اثربخشی دارچین مکمل گلیکولیپید(glycolipid) متابولیسم در دیابت T2DM: A متاآنالیز و مرور سیستماتیک
Background: Cinnamon is a spice used in cooking and in large quantities as a medical
complement with hypoglycemic and lipid-lowering properties. The potential
pharmacological mechanisms underlying cinnamon’s anti-diabetic properties and
its active ingredients have not been adequately determined. The current meta-analysis
aims to systematically review the potential pharmacological mechanisms underlying
the hypoglycemic and hypolipidemic efficacy of cinnamon administration and
summarize clinical recommendations of cinnamon and its active ingredients.
Method: Relevant randomized clinical trials (RCTs) were identified through a
literature search that spanned the years January 2005 to April 2022. Retrieve
electronic databases including Web of Science, PubMed, Embase,Medline, and the
Cochrane Library. To obtain standardized mean differences (SMDs), continuous
outcomes were pooled and 95 percent confidence intervals (CIs) were provided.
Categorical outcomes were aggregated to calculate relative risks (RRs) and were
accompanied by 95% CIs. Heterogeneitywasmeasured using the Cochrane Q-test
and I2 statistics,with a p < 0.05 considered as substantial heterogeneity. If I2 was less
than 50%, a fixed effect model was employed; otherwise, a random effect model
was used. Subgroup analyses and sensitivity analyses were performed to identify
the origins of heterogeneity. Publication bias was retrieved by means of a funnelplot
analysis and Egger’s test. The data were analyzed using revman (V.5.3) and stata
(V.15) software packages.
Results: These 16 RCTs included a total of 1,020 patients who were followed for a
duration ranging from 40 days to 4months. According to the current meta-analysis
results, glycolipid levels in diabetic individuals who received cinnamon were
significantly improved as compared to those who got placebo (All p < 0.05). An
adverse effect was only detected in one patient.